Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 1072833-77-2
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15DAY
Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram
Supply Ability: G,KG,TON
Appearance:: |
Solid Powder |
CAS NO:: |
1072833-77-2 |
Molecular Formula:: |
C14H19BCl2N2O4 |
Molecular Weight:: |
361.02900 |
EINECS NO:: |
810-246-8 |
MDL NO:: |
MFCD18251438 |
Appearance:: |
Solid Powder |
CAS NO:: |
1072833-77-2 |
Molecular Formula:: |
C14H19BCl2N2O4 |
Molecular Weight:: |
361.02900 |
EINECS NO:: |
810-246-8 |
MDL NO:: |
MFCD18251438 |
Product Description:
Product Name: MLN2238 CAS NO: 1072833-77-2
Synonyms:
[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid;
B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid;
(R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid;
Chemical & Physical Properties:
Appearance: Solid powder
Assay :≥99.00%
Density: 1.306 g/cm3
Soluble: Soluble in DMSO, not in water
Index of Refraction: 1.546
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, developed by Takeda. It acts as a proteasome inhibitor and has orphan drug status in the US.
On November 20, 2015, the U.S. Food and Drug Administration approved ixazomib for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.
